2024-09-23 13:00:00
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Varenicline Newbury in Sweden. Approval in Iceland is expected to follow upon finalized national review.
Varenicline Newbury, is a generic version of Champix. A prescription medicine indicated for the treatment of smoking cessation in adults.
“The successful approval of Varenicline highlights Newbury's capability to offer a diverse and comprehensive portfolio. Further to this Varenicline Newbury is filling a gap in the market as few alternatives have been available for patients in the last years.” says Mr Lars Minor CEO of Newbury.